Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 244

Drug Profile

B 244

Alternative Names: AOB 101; AOB 102; AOB 103; AOB 201; AOB 202; AOB 203; B244; Nitrosomonas eutropha D23

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AOBiome
  • Developer AOBiome; Novella Clinical
  • Class Anti-inflammatories; Antiacnes; Antiallergics; Antibacterials; Antihypertensives; Antimigraines; Antipruritics; Bacteria; Skin disorder therapies
  • Mechanism of Action Bacteria replacements; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Acne vulgaris
  • Phase II Atopic dermatitis; Hypertension; Pruritus; Rosacea
  • Phase I/II Allergic rhinitis; Eczema
  • No development reported Migraine; Skin disorders; Staphylococcal infections

Most Recent Events

  • 05 Jan 2024 AoBiome Therapeutics plans phase III trials in Atopic dermatitis in the second half of 2024
  • 05 Jan 2024 Maruho and AOB Pharma agree to co-develop B 244 in Japan for Atopic Dermatitis and Pruritus
  • 06 Apr 2023 AOBiome Therapeutics has patent protection for composition of matter patent for proprietary strain of Ammonia Oxidizing Bacteria (AOB) in Europe and Hong Kong
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top